PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22004922-8	2011	In summary, pretreatment with parthenolide attenuates the febrile response during LPS-induced systemic inflammation by reducing circulating IL-6 and TNFalpha and decreasing hypothalamic NFkappaB/NF-IL6 activation, oxidative stress and expression of COX2.	parthenolide	30-42	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	249-253	
23576578-6	2013	Ro-106-9920 or parthenolide, agents that inhibit the initial steps of NF-kappaB activation, blocked ANG II-induced p65 NF-kappaB nuclear localization, COX-2 protein expression, beta-arrestin recruitment, and AT1AR internalization without inhibiting ANG II-induced p42/44 ERK activation.	parthenolide	15-27	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	151-156	
19585671-8	2009	In addition, parthenolide also increased IkappaBalpha expression and reduced Cox-2 expression in a time-dependent manner.	parthenolide	13-25	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	77-82	
19585671-10	2009	IkappaBalpha and Cox-2 are likely involved in such inhibitory effect of parthenolide on VSMC proliferation.	parthenolide	72-84	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	17-22	
19303104-12	2009	Parthenolide dose dependently suppressed tumor necrosis factor-alpha induced cyclooxygenase-2 expression and prevented nuclear factor-kappaB phosphorylation as well as nuclear factor-kappaB nuclear translocation and IkappaBalpha phosphorylation/degradation.	parthenolide	0-12	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	77-93